ERK Cancer Research Results

ERK, ERK signaling: Click to Expand ⟱
Source:
Type:
MAPK3 (ERK1)
ERK proteins are kinases that activate other proteins by adding a phosphate group. An overactivation of these proteins causes the cell cycle to stop.
The extracellular signal-regulated kinase (ERK) signaling pathway is a crucial component of the mitogen-activated protein kinase (MAPK) signaling cascade, which plays a significant role in regulating various cellular processes, including proliferation, differentiation, and survival. high levels of phosphorylated ERK (p-ERK) in tumor samples may indicate active ERK signaling and could correlate with aggressive tumor behavior

EEk singaling is frequently activated and is often associated with aggressive tumor behavior, treatment resistance, and poor outcomes.
Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
2288- AgNPs,    Silver Nanoparticle-Mediated Cellular Responses in Various Cell Lines: An in Vitro Model
- Review, Var, NA
*ROS↑, Akt↓, ERK↓, DNAdam↑, Ca+2↑, ROS↑, MMP↓, Cyt‑c↑, TumCCA↑, DNAdam↑, Apoptosis↑, P53↑, p‑ERK↑, ER Stress↑, cl‑ATF6↑, GRP78/BiP↑, CHOP↑, UPR↑,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
171- Api,    Apigenin in cancer therapy: anti-cancer effects and mechanisms of action
- Review, Var, NA
PI3K/Akt↓, NF-kB↓, CK2↓, FOXO↓, MAPK↝, ERK↓, p‑JAK↓, Wnt/(β-catenin)↓, ROS↑, CDC25↓, p‑STAT↓, DNAdam↑,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
3162- Ash,    Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A
- Review, Var, NA
lipid-P↓, SOD↑, GPx↑, P53↑, Bcl-2↑, E6↓, E7↓, pRB↑, CycB/CCNB1↑, CDC2↑, P21↑, PCNA↓, ALDH1A1↓, Vim↓, Glycolysis↓, cMyc↓, BAX↑, NF-kB↓, Casp3↑, CHOP↑, DR5↑, ERK↓, Wnt↓, β-catenin/ZEB1↓, Akt↓, HSP90↓,
4815- ASTX,    The Promising Effects of Astaxanthin on Lung Diseases
- Review, Var, NA
Dose↑, *BioAv↝, *BioAv↝, *antiOx↑, *NRF2↑, *ERK↓,
5577- B-Gluc,    Lentinan progress in inflammatory diseases and tumor diseases
- Review, Var, NA - Review, IBD, NA
AntiTum↑, GutMicro↑, *Inflam↓, *TNF-α↓, *NF-kB↓, ChemoSen↑, OS↑, Imm↑, IL6↓, ERK↓, MAPK↓, *antiOx↑, eff↑,
5502- Ba,    An overview of pharmacological activities of baicalin and its aglycone baicalein: New insights into molecular mechanisms and signaling pathways
- Review, Var, NA
*AntiCan↑, *antiOx↑, *hepatoP↑, *neuroP↑, *ROS↓, Ca+2↑, ROS↑, BAX↑, Casp3↑, Casp9↑, Cyt‑c↑, MMP↓, Mcl-1↓, PI3K↓, Akt↓, mTOR↓, BAD↓, ERK↓, MEK↓, DR5↑, Fas↑, TumMeta↓, EMT↓, SMAD4↓, TGF-β↓, MMP9↓, MMP2↓, HIF-1↓, 12LOX↓,
2670- BBR,    Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases
- Review, Var, NA
*Inflam↓, *antiOx↑, *Ca+2↓, *BioAv↓, *BioAv↑, *BioAv↑, *angioG↑, *MAPK↓, *AMPK↓, *NF-kB↓, VEGF↓, PI3K↓, Akt↓, MMP2↓, Bcl-2↓, ERK↓,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
2760- BetA,    A Review on Preparation of Betulinic Acid and Its Biological Activities
- Review, Var, NA - Review, Stroke, NA
AntiTum↑, Cyt‑c↑, Smad1↑, Sepsis↓, NF-kB↓, ICAM-1↓, MCP1↓, MMP9↓, COX2↓, PGE2↓, ERK↓, p‑Akt↓, *ROS↓, *LDH↓, *hepatoP↑, *SOD↑, *Catalase↑, *GSH↑, *AST↓, *ALAT↓, *RenoP↑, *ROS↓, *α-SMA↓,
5680- BML,    Anticancer properties of bromelain: State-of-the-art and recent trends
- Review, Var, NA
*Inflam↓, *Bacteria↓, *Pain↓, *Diar↓, *Wound Healing↑, ERK↓, JNK↓, XIAP↓, HSP27↓, β-catenin/ZEB1↓, HO-1↓, lipid-P↓, ACSL4↑, ROS↑, SOD↑, Catalase↓, GSH↓, MDA↓, Casp3↓, Casp9↑, DNAdam↑, Apoptosis↑, NF-kB↓, P53↑, MAPK↓, APAF1↑, Cyt‑c↓, CD44↓, Imm↑, ATG5↑, LC3I↑, Beclin-1↑, IL2↓, IL4↓, IFN-γ↓, COX2↓, iNOS↓, ChemoSen↑, RadioS↑, Dose↝, other↓,
2776- Bos,    Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities
- Review, Var, NA
*5LO↓, *TNF-α↓, *MMP3↓, *COX1↓, *COX2↓, *PGE2↓, *Th2↑, *Catalase↑, *SOD↑, *NO↑, *PGE2↑, *IL1β↓, *IL6↓, *Th1 response↓, *Th2↑, *iNOS↓, *NO↓, *p‑JNK↓, *p38↓, GutMicro↑, p‑Akt↓, GSK‐3β↓, cycD1/CCND1↓, Akt↓, STAT3↓, CSCs↓, AR↓, P21↑, DR5↑, CHOP↑, Casp3↑, Casp8↑, cl‑PARP↑, DNAdam↑, p‑RB1↓, FOXM1↓, TOP2↓, CDC25↓, p‑CDK1↓, p‑ERK↓, MMP9↓, VEGF↓, angioG↓, ROS↑, Cyt‑c↑, AIF↑, Diablo↑, survivin↓, ICAD↓, ChemoSen↑, SOX9↓, ER Stress↑, GRP78/BiP↑, cal2↓, AMPK↓, mTOR↓, ROS↓,
2775- Bos,    The journey of boswellic acids from synthesis to pharmacological activities
- Review, Var, NA - Review, AD, NA - Review, PSA, NA
ROS↑, ER Stress↑, TumCG↓, Apoptosis↑, Inflam↓, ChemoSen↑, Casp↑, ERK↓, cl‑PARP↑, AR↓, cycD1/CCND1↓, VEGFR2↓, CXCR4↓, radioP↑, NF-kB↓, VEGF↓, P21↑, Wnt↓, β-catenin/ZEB1↓, Cyt‑c↑, MMP2↓, MMP1↓, MMP9↓, PI3K↓, MAPK↓, JNK↑, *5LO↓, *NRF2↑, *HO-1↑, *MDA↓, *SOD↑, *hepatoP↑, *ALAT↓, *AST↓, *LDH↑, *CRP↓, *COX2↓, *GSH↑, *ROS↓, *Imm↑, *Dose↝, *eff↑, *neuroP↑, *cognitive↑, *IL6↓, *TNF-α↓,
2767- Bos,    The potential role of boswellic acids in cancer prevention and treatment
- Review, Var, NA
*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2↓, MMP9↓, CXCR4↓, VEGF↓, eff↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, eff↑, MMP1↓, MMP2↓, eff↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,
1652- CA,    Caffeic Acid and Diseases—Mechanisms of Action
- Review, Var, NA
Dose∅, ROS⇅, NF-kB↓, STAT3↓, VEGF↓, MMP9↓, HSP70/HSPA5↑, AST↝, ALAT↝, ALP↝, Hif1a↓, IL6↓, IGF-1R↓, P21↑, iNOS↓, ERK↓, Snail↓, BID↑, BAX↑, Casp3↑, Casp7↑, Casp9↑, cycD1/CCND1↓, Vim↓, β-catenin/ZEB1↓, COX2↓, ROS↑,
1650- CA,    Adjuvant Properties of Caffeic Acid in Cancer Treatment
- Review, Var, NA
ROS↑, antiOx↑, Inflam↓, AntiCan↑, NF-kB↓, STAT3↓, ERK↓, ChemoSen↑, RadioS↑, AMPK↑, eff↑, selectivity↑, COX2↓, Dose∅, PHDs↓, MMP9↓, MMP2↓, Dose∅, Dose∅, Ca+2↑, Dose?, MMP↓, RadioS↑,
5888- CAR,    Therapeutic application of carvacrol: A comprehensive review
- Review, Var, NA - Review, Stroke, NA - Review, Diabetic, NA - Review, Park, NA
*antiOx↑, *AntiCan↑, *AntiDiabetic↑, *cardioP↑, *Obesity↓, *hepatoP↑, *AntiAg↑, *Bacteria↓, *Imm↑, MMP2↓, MMP9↓, Apoptosis↓, MMP↓, ERK↓, PI3K↓, ALAT↓, *ROS↓, *Catalase↑, *SOD↑, *GPx↑, *AST↓, *LDH↓, *necrosis↓, ROS↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, NOTCH↓, IL6↓, chemoP↑, *Pain↓, *neuroP↑, *TRPM7↓, *motorD↑, *NF-kB↓, *COX2↓, *MDA↓,
5894- CAR,    Targeting Gastrointestinal Cancers with Carvacrol: Mechanistic Insights and Therapeutic Potential
- Review, Var, NA
AntiCan↑, Apoptosis↑, Inflam↓, angioG↓, TumMeta↓, selectivity↑, BioAv↑, ChemoSen↑, Dose↝, TumCP↓, hepatoP↑, Casp3↑, Casp9↑, Bcl-2↓, ROS↑, GSH↓, BAX↑, Casp7↑, Casp8↑, Cyt‑c↑, Fas↑, FADD↑, P53↑, Bcl-2↓, TumMeta↓, TumCMig↓, TumCI↓, E-cadherin↑, TIMP2↑, TIMP3↑, N-cadherin↓, ZEB2↓, *lipid-P↓, *AST↓, *ALAT↓, *ALP↓, *LDH↓, *SOD↑, *Catalase↑, *GPx↑, *GSR↑, selectivity↑, cl‑PARP↑, ERK↓, p38↑, OS↑, AFP↓, COX2↓, VEGF↓, PCNA↓, Ki-67↓, TNF-α↓, BioAv↓,
5893- CAR,  TV,    Thymol and Carvacrol: Molecular Mechanisms, Therapeutic Potential, and Synergy With Conventional Therapies in Cancer Management
- Review, Var, NA
*Inflam↓, AntiCan↑, PI3K↓, Akt↓, mTOR↓, NOTCH↓, PIK3CA↓, EGFR↓, Hif1a↓, VEGF↓, ChemoSen↑, RadioS↑, eff↝, *cardioP↑, *neuroP↑, *hepatoP↑, Apoptosis↑, MMP↓, Casp3↑, ROS↑, DNAdam↑, eff↑, BAX↑, BAD↑, FasL↑, Cyt‑c↑, Casp9↑, Casp8↑, TumCCA↑, P21↑, Smo↓, Gli1↓, JNK↑, ERK↓, MAPK↓, TRPM7↓, Wnt/(β-catenin)↓, BioAv↝, BioAv↑,
6017- CGA,    Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment
- Review, Var, NA
AntiCan↑, *chemoP↑, TNF-α↓, COX2↓, IL6↓, eff↑, PD-L1↓, *cognitive↓, *Aβ↓, *TAC↑, *SOD↑, *eff↑, *eff↑, ChemoSen↑, tumCV↓, Apoptosis↑, ERK↓, chemoP↑, *GPx↑, *GSTs↑, *GSH↑, *SOD↑, *Catalase↑, *ROS↓, *lipid-P↓, *MDA↓, *Casp3↓, *HO-1↓, cardioP↑, radioP↑,
6026- CGA,    Chlorogenic Acid: The Conceivable Chemosensitizer Leading to Cancer Growth Suppression
- Review, Var, NA
ChemoSen↑, AMPK↑, EGFR↓, PI3K↓, mTOR↓, Hif1a↓, VEGF↓, MAPK↓, ERK↓, DNAdam↑, TOP1↓, TOP2↓, Apoptosis↑, *BioAv↝, *Half-Life↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
649- EGCG,  CUR,  PI,    Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
*BioEnh↑, EGFR↓, HER2/EBBR2↓, IGF-1↓, MAPK↓, ERK↓, RAS↓, Raf↓, NF-kB↓, p‑pRB↓, TumCCA↑, Glycolysis↓, Warburg↓, HK2↓, Pyruv↓,
2992- EGCG,    Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity
- Review, Var, NA
AP-1↓, Sp1/3/4↓, NF-kB↓, ERK↓, P-gp↓, HSP27↓, β-catenin/ZEB1↓, MMPs↓, TNF-α↓, IL1β↓, MMP2↓,
1324- EMD,    Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin
- Review, Var, NA
*toxicity↑, *BioAv↓, Akt↓, ERK↓, ROS↑, MMP↓, Bcl-2↓, BAX↑, TumCCA↑,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2829- FIS,    Fisetin: An anticancer perspective
- Review, Var, NA
TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓, CSCs↓,
2830- FIS,    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
- Review, Var, NA
TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
2843- FIS,    Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
- Review, Var, NA
NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,
5148- GamB,    Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics
- Review, Var, NA
AntiCan↑, angioG↓, ChemoSen↑, RadioS↑, VEGF↓, MMP2↓, MMP9↓, Telomerase↓, TrxR↓, ERK↓, HSP90↓, ROS↑, SIRT1↑, survivin↓, cFLIP↓, Casp3↑, Casp8↑, Casp9↑, BAD↓, BID↓, Bcl-2↓, BAX↑, STAT3↓, hTERT/TERT↓, NF-kB↓, Myc↓, Hif1a↓, FOXD3↑, BioAv↓, BioAv↑, P53↑, eff↓, OCR↓, MMP↓, PI3K↓, Akt↓, BBB↑, TumCG↓, TumMeta↓, BioAv↑,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2894- HNK,    Pharmacological features, health benefits and clinical implications of honokiol
- Review, Var, NA - Review, AD, NA
*BioAv↓, *neuroP↑, *BBB↑, *ROS↓, *Keap1↑, *NRF2↑, *Casp3↓, *SIRT3↑, *Rho↓, *ERK↓, *NF-kB↓, angioG↓, RAS↓, PI3K↓, Akt↓, mTOR↓, *memory↑, *Aβ↓, *PPARγ↑, *PGC-1α↑, NF-kB↓, Hif1a↓, VEGF↓, HO-1↓, FOXM1↓, p27↑, P21↑, CDK2↓, CDK4↓, CDK6↓, cycD1/CCND1↓, Twist↓, MMP2↓, Rho↑, ROCK1↑, TumCMig↓, cFLIP↓, BMPs↑, OCR↑, ECAR↓, *AntiAg↑, *cardioP↑, *antiOx↑, *ROS↓, P-gp↓,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
3264- Lyco,    Pharmacological potentials of lycopene against aging and aging‐related disorders: A review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
*antiOx↑, *ROS↓, *SOD↑, *Catalase↑, *GSH↑, *GSTs↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *iNOS↓, *NO↓, *TAC↑, *NOX4↓, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *IL1β↓, *TNF-α↓, *TLR2↓, *TLR4↓, *VCAM-1↓, *ICAM-1↓, *STAT3↓, *NF-kB↓, *ERK↓, *BP↓, ROS↓, PGE2↓, cardioP↑, *neuroP↑, *creat↓, *RenoP↑, *CRM↑,
3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE/CCNE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1/CCND1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,
4792- Lyco,    A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy
- Review, Var, NA
*AntiCan↑, *antiOx↑, Inflam↓, Wnt↓, β-catenin/ZEB1↓, *ROS↓, BioAv↑, ROS↓, Risk↓, PGE2↓, COX2↓, p‑ERK↓, P21↑, MMP7↓, MMP9↓, ChemoSen↑, eff↑,
4647- OLEC,    Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer
- Review, Var, NA
*Inflam↓, AntiCan↑, *COX2↓, *ROS↓, *TNF-α↓, *IL1β↓, *iNOS↓, TumCP↓, *AntiAg↑, mTOR↓, STAT3↓, ERK↓, p‑Akt↓, Bcl-2↓, ROS↑, PSA↓,
1661- PBG,    Propolis: a natural compound with potential as an adjuvant in cancer therapy - a review of signaling pathways
- Review, Var, NA
JNK↓, ERK↓, Akt↓, NF-kB↓, FAK↓, MAPK↓, PI3K↓, Akt↓, P21↑, p27↑, TRAIL↑, BAX↑, P53↑, ERK↓, ChemoSen↑, RadioS↑, Glycolysis↓, HK2↓, PKM2↓, LDHA↓, PFK↓,
1668- PBG,    Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms
- Review, Var, NA
antiOx↑, Inflam↓, AntiCan↑, TumCP↓, Apoptosis↑, eff↝, MMPs↓, TNF-α↓, iNOS↓, COX2↓, IL1β↑, *BioAv↓, BAX↑, Casp3↑, Cyt‑c↑, Bcl-2↓, eff↑, selectivity↑, P53↑, ROS↑, Casp↑, eff↑, ERK↓, Dose∅, TRAIL↑, NF-kB↑, ROS↑, Dose↑, MMP↓, DNAdam↑, TumAuto↑, LC3II↑, p62↓, EGF↓, Hif1a↓, VEGF↓, TLR4↓, GSK‐3β↓, NF-kB↓, Telomerase↓, ChemoSen↑, ChemoSideEff↓,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
4827- QC,  CUR,    Synthetic Pathways and the Therapeutic Potential of Quercetin and Curcumin
- Review, Var, NA
*AntiCan↑, *Inflam↓, *Bacteria↓, *AntiDiabetic↑, *ROS↓, *SOD↑, *Catalase↑, *GSH↑, *NRF2↑, *Trx↑, *IronCh↑, *MDA↑, cycD1/CCND1↓, PI3K↓, Casp3↑, BAX↑, ChemoSen↑, ROS↑, eff↑, MMP↓, Cyt‑c↑, Akt↓, ERK↓,
3343- QC,    Quercetin, a Flavonoid with Great Pharmacological Capacity
- Review, Var, NA - Review, AD, NA - Review, Arthritis, NA
*antiOx↑, *ROS↓, *angioG↓, *Inflam↓, *BioAv↓, *Half-Life↑, *GSH↑, *SOD↑, *Catalase↑, *Nrf1↑, *BP↓, *cardioP↑, *IL10↓, *TNF-α↓, *Aβ↓, *GSK‐3β↓, *tau↓, *neuroP↑, *Pain↓, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL17↓, *MCP1↓, PKCδ↓, ERK↓, BAX↓, cMyc↓, KRAS↓, ROS↓, selectivity↑, tumCV↓, Apoptosis↑, TumCCA↑, eff↑, P-gp↓, eff↑, eff↑, eff↑, eff↑, CycB/CCNB1↓, CDK1↓, CDK4↓, CDK2↓, TOP2↓, Cyt‑c↑, cl‑PARP↑, MMP↓, HSP70/HSPA5↓, HSP90↓, MDM2↓, RAS↓, eff↑,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,

Showing Research Papers: 1 to 50 of 69
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 69

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 3,   antiOx⇅, 1,   Catalase↓, 2,   Catalase↑, 1,   CYP1A1↓, 1,   CYP1A1↑, 1,   CYP2E1↑, 1,   GPx↑, 3,   GSH↓, 5,   GSH↑, 1,   GSR↑, 1,   GSTA1↑, 1,   HO-1↓, 5,   HO-1↑, 3,   HO-2↓, 1,   Keap1↓, 1,   lipid-P?, 1,   lipid-P↓, 3,   lipid-P↑, 1,   MDA↓, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↓, 3,   NRF2↑, 5,   ROS↓, 10,   ROS↑, 33,   ROS⇅, 1,   SOD↓, 1,   SOD↑, 4,   SOD1↑, 1,   SOD2↑, 1,   Trx1↑, 1,   TrxR↓, 2,  

Metal & Cofactor Biology ⓘ

Tf↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   AIF↑, 2,   ATP↓, 1,   CDC2↓, 4,   CDC2↑, 1,   CDC25↓, 7,   EGF↓, 2,   MEK↓, 2,   MMP↓, 18,   MMP↑, 1,   OCR↓, 2,   OCR↑, 1,   Raf↓, 2,   XIAP↓, 7,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   ACC↑, 1,   ACSL4↑, 1,   ALAT↓, 2,   ALAT↝, 1,   AMPK↓, 1,   AMPK↑, 3,   cMyc↓, 7,   p‑cMyc↑, 1,   CYP3A4↓, 1,   ECAR↓, 1,   ECAR↝, 1,   FASN↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 6,   HK2↓, 4,   lactateProd↓, 1,   LDH↓, 1,   LDHA↓, 1,   LDL↓, 1,   PDK1?, 2,   PDK1↓, 1,   PFK↓, 1,   PI3K/Akt↓, 1,   PIK3CA↓, 1,   PKM2↓, 1,   PPARα↓, 2,   PPARγ↑, 1,   Pyruv↓, 1,   SIRT1↓, 1,   SIRT1↑, 2,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 27,   Akt↑, 1,   p‑Akt↓, 6,   APAF1↑, 3,   Apoptosis↓, 1,   Apoptosis↑, 18,   BAD↓, 2,   BAD↑, 2,   BAX↓, 2,   BAX↑, 21,   Bax:Bcl2↑, 2,   Bcl-2↓, 14,   Bcl-2↑, 2,   Bcl-xL↓, 4,   BID↓, 1,   BID↑, 1,   BIM↑, 2,   Casp↑, 4,   Casp3↓, 4,   Casp3↑, 19,   cl‑Casp3↑, 3,   Casp7↑, 4,   cl‑Casp7↑, 1,   Casp8↑, 11,   cl‑Casp8↑, 3,   Casp9↑, 15,   cl‑Casp9↑, 4,   proCasp9↓, 1,   cFLIP↓, 4,   Chk2↓, 1,   CK2↓, 3,   Cyt‑c↓, 1,   Cyt‑c↑, 22,   Diablo↑, 4,   DR4↑, 2,   DR5↑, 9,   FADD↑, 1,   Fas↑, 6,   FasL↑, 2,   hTERT/TERT↓, 4,   IAP1↓, 2,   IAP2↓, 1,   cl‑IAP2↑, 1,   ICAD↓, 1,   iNOS↓, 8,   JNK↓, 3,   JNK↑, 5,   p‑JNK↓, 1,   MAPK↓, 10,   MAPK↑, 2,   MAPK↝, 1,   Mcl-1↓, 6,   MDM2↓, 7,   Myc↓, 2,   NICD↓, 1,   NOXA↑, 1,   p27↑, 4,   p38↓, 1,   p38↑, 2,   PUMA↑, 1,   survivin↓, 10,   Telomerase↓, 6,   TRAIL↑, 3,   TRAILR↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

FOXD3↑, 1,   HER2/EBBR2↓, 4,   p‑HER2/EBBR2↓, 1,   SOX9↓, 1,   Sp1/3/4↓, 3,   TSC2↑, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 2,   ac‑H3↑, 1,   ac‑H4↑, 1,   other↓, 2,   other↝, 1,   pRB↑, 1,   p‑pRB↓, 2,   tumCV↓, 6,  

Protein Folding & ER Stress ⓘ

cl‑ATF6↑, 1,   CHOP↑, 7,   eIF2α↑, 1,   p‑eIF2α↑, 2,   ER Stress↓, 1,   ER Stress↑, 9,   GRP78/BiP↑, 6,   HSP27↓, 2,   HSP27↝, 1,   HSP70/HSPA5↓, 2,   HSP70/HSPA5↑, 1,   HSP70/HSPA5↝, 1,   HSP90↓, 3,   HSPs↓, 1,   IRE1↑, 1,   p‑PERK↑, 1,   UPR↑, 2,   XBP-1↓, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 2,   BNIP3↑, 1,   LC3B-II↑, 1,   LC3I↑, 1,   LC3II↑, 2,   p62↓, 1,   TumAuto↑, 4,  

DNA Damage & Repair ⓘ

ATM↑, 1,   CHK1↓, 1,   DNAdam↓, 2,   DNAdam↑, 14,   DNMTs↓, 1,   P53?, 1,   P53↓, 2,   P53↑, 17,   PARP↑, 1,   cl‑PARP↑, 13,   PARP1↑, 1,   PCNA↓, 6,   SIRT6↑, 1,   γH2AX↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 3,   p‑CDK1↓, 1,   CDK2↓, 14,   CDK4↓, 11,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 6,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 17,   cycE/CCNE↓, 6,   E2Fs↓, 1,   P21↑, 16,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 3,   Securin↓, 1,   TumCCA↑, 16,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   CD133↓, 2,   CD44↓, 2,   CDK8↓, 1,   cFos↓, 3,   cMET↓, 1,   p‑cMET↑, 1,   CSCs↓, 2,   EMT↓, 11,   EMT↑, 1,   ERK↓, 41,   p‑ERK↓, 7,   p‑ERK↑, 1,   FOXM1↓, 2,   FOXO↓, 1,   p‑FOXO3↓, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   p‑GSK‐3β↓, 2,   HDAC↓, 3,   IGF-1↓, 4,   IGF-1R↓, 1,   IGFBP3↑, 1,   Let-7↑, 1,   mTOR↓, 15,   p‑mTOR↓, 1,   mTORC1↓, 1,   mTORC2↓, 1,   Nanog↓, 1,   Nestin↓, 1,   NOTCH↓, 4,   NOTCH1↓, 1,   NOTCH1↑, 1,   OCT4↓, 1,   PI3K↓, 19,   PTEN↑, 4,   RAS↓, 5,   RAS↑, 1,   Shh↓, 1,   Smo↓, 1,   SOX2↓, 1,   p‑STAT↓, 1,   STAT3↓, 11,   p‑STAT3↓, 3,   TAZ↓, 1,   TCF↑, 1,   TCF-4↓, 1,   TOP1↓, 4,   TOP2↓, 6,   TOP2↑, 1,   TRPM7↓, 1,   TumCG↓, 6,   Wnt↓, 11,   Wnt/(β-catenin)↓, 3,  

Migration ⓘ

AEG1↓, 1,   AntiAg↓, 1,   AntiAg↑, 1,   AP-1↓, 3,   Ca+2↑, 6,   Ca+2↝, 1,   cal2↓, 1,   cal2↑, 1,   Cdc42↑, 1,   CLDN1↓, 1,   CLDN2↓, 1,   CXCL12↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 8,   FAK↓, 6,   p‑FAK↓, 1,   Fibronectin↓, 2,   ITGB1↓, 1,   ITGB4↓, 1,   ITGB6↓, 1,   Ki-67↓, 3,   KRAS↓, 1,   miR-200b↑, 1,   MMP-10↓, 1,   MMP1↓, 6,   MMP13↓, 1,   MMP2↓, 21,   MMP3↓, 2,   MMP7↓, 4,   MMP9↓, 25,   MMPs↓, 6,   N-cadherin↓, 6,   PDGF↓, 2,   PKCδ↓, 7,   Rho↓, 1,   Rho↑, 1,   ROCK1↓, 1,   ROCK1↑, 1,   Slug↓, 2,   Smad1↑, 1,   SMAD3↓, 1,   SMAD4↓, 1,   Snail↓, 7,   TET1↓, 1,   TET1↑, 1,   TGF-β↓, 5,   TIMP1↑, 1,   TIMP2↑, 3,   TIMP3↑, 1,   TSP-1↑, 1,   TumCA↓, 1,   TumCI↓, 10,   TumCMig↓, 7,   TumCP↓, 14,   TumMeta↓, 11,   TumMeta↑, 1,   Twist↓, 7,   uPA↓, 8,   Vim↓, 7,   ZEB2↓, 1,   β-catenin/ZEB1↓, 13,  

Angiogenesis & Vasculature ⓘ

angioG↓, 16,   ATF4↑, 2,   EGFR↓, 16,   p‑EGFR↓, 1,   Endoglin↑, 1,   HIF-1↓, 1,   Hif1a↓, 12,   NO↓, 2,   p‑PDGFR-BB↓, 1,   PHDs↓, 1,   VEGF↓, 25,   VEGFR2↓, 4,  

Barriers & Transport ⓘ

BBB↑, 1,   NHE1↓, 1,   P-gp↓, 4,  

Immune & Inflammatory Signaling ⓘ

CD4+↓, 1,   COX1↓, 1,   COX2↓, 20,   COX2↑, 1,   CXCR4↓, 5,   ICAM-1↓, 1,   IFN-γ↓, 2,   IKKα↓, 2,   IL1↓, 2,   IL1↑, 1,   IL10↓, 2,   IL1α↓, 1,   IL1β↓, 2,   IL1β↑, 1,   IL2↓, 1,   IL2↑, 1,   IL4↓, 1,   IL4↑, 1,   IL6↓, 11,   IL8↓, 2,   Imm↑, 2,   Inflam↓, 8,   JAK↓, 1,   p‑JAK↓, 1,   JAK1↓, 2,   JAK2↓, 1,   MCP1↓, 3,   MIP2↓, 1,   NF-kB↓, 32,   NF-kB↑, 2,   p‑NF-kB↑, 1,   p65↓, 1,   PD-L1↓, 2,   PGE2↓, 9,   PSA↓, 2,   TLR4↓, 2,   TNF-α↓, 9,   TNF-α↑, 1,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 6,   CDK6↓, 7,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 11,   BioAv↑, 13,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 28,   CYP1A2↓, 1,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   Dose?, 1,   Dose↓, 1,   Dose↑, 3,   Dose↝, 6,   Dose∅, 6,   eff↓, 2,   eff↑, 34,   eff↝, 2,   Half-Life↓, 2,   Half-Life↝, 1,   MDR1↓, 1,   P450↓, 2,   RadioS↑, 11,   selectivity↑, 10,  

Clinical Biomarkers ⓘ

AFP↓, 1,   ALAT↓, 2,   ALAT↝, 1,   ALP↓, 1,   ALP↝, 1,   AR↓, 6,   ascitic↓, 1,   AST↝, 1,   BMPs↑, 2,   E6↓, 1,   E7↓, 1,   EGFR↓, 16,   p‑EGFR↓, 1,   FOXM1↓, 2,   GutMicro↑, 3,   HER2/EBBR2↓, 4,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 4,   IL6↓, 11,   Ki-67↓, 3,   KRAS↓, 1,   LDH↓, 1,   Myc↓, 2,   PD-L1↓, 2,   PSA↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 11,   AntiTum↑, 3,   cardioP↑, 5,   chemoP↑, 4,   chemoPv↑, 2,   ChemoSideEff↓, 1,   hepatoP↑, 1,   neuroP↑, 1,   OS↑, 2,   radioP↑, 2,   RenoP↑, 2,   Risk↓, 2,   toxicity↓, 2,   TumVol↓, 1,   TumW↓, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 450

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 16,   Catalase↑, 12,   GPx↑, 4,   GPx1↑, 1,   GSH↑, 8,   GSR↑, 3,   GSTA1↑, 1,   GSTs↑, 3,   HO-1↓, 1,   HO-1↑, 4,   Keap1↑, 1,   lipid-P↓, 5,   MDA↓, 4,   MDA↑, 1,   NOX4↓, 1,   Nrf1↑, 1,   NRF2↑, 8,   ROS↓, 21,   ROS↑, 1,   SIRT3↑, 1,   SOD↑, 12,   SOD1↑, 1,   SOD2↑, 1,   TAC↑, 2,   Trx↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 2,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 4,   AMPK↓, 1,   CRM↑, 1,   LDH↓, 3,   LDH↑, 1,   NADPH↓, 1,   PPARγ↑, 1,  

Cell Death ⓘ

Casp3↓, 3,   iNOS↓, 4,   p‑JNK↓, 1,   MAPK↓, 2,   MAPK↑, 1,   necrosis↓, 1,   p38↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↝, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 3,   GSK‐3β↓, 1,   STAT3↓, 1,   TRPM7↓, 1,  

Migration ⓘ

5LO↓, 2,   AntiAg↑, 3,   Ca+2↓, 1,   Ca+2↝, 1,   MMP3↓, 1,   PKCδ↓, 1,   p‑Rac1↓, 1,   Rho↓, 1,   VCAM-1↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   angioG↑, 1,   NO↓, 3,   NO↑, 1,  

Barriers & Transport ⓘ

BBB↑, 2,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 7,   CRP↓, 1,   ICAM-1↓, 1,   IKKα↑, 1,   IL1↓, 1,   IL10↓, 2,   IL17↓, 1,   IL1β↓, 4,   IL6↓, 4,   IL8↓, 1,   Imm↑, 2,   Inflam↓, 14,   MCP1↓, 1,   NF-kB↓, 8,   PGE2↓, 2,   PGE2↑, 1,   Th1 response↓, 1,   Th2↑, 2,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 8,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 4,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 8,   BioAv↑, 5,   BioAv↝, 3,   BioEnh↑, 1,   Dose↝, 3,   eff↑, 3,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 4,   ALP↓, 2,   AST↓, 6,   BP↓, 2,   creat↓, 1,   CRP↓, 1,   IL6↓, 4,   LDH↓, 3,   LDH↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 5,   AntiDiabetic↑, 2,   cardioP↑, 5,   chemoP↑, 1,   cognitive↓, 1,   cognitive↑, 1,   hepatoP↑, 7,   memory↑, 1,   motorD↑, 1,   neuroP↑, 10,   Obesity↓, 1,   Pain↓, 3,   RenoP↑, 3,   toxicity↓, 1,   toxicity↑, 1,   toxicity↝, 1,   Wound Healing↑, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 3,   Diar↓, 1,  
Total Targets: 126

Scientific Paper Hit Count for: ERK, ERK signaling
6 Fisetin
4 Silymarin (Milk Thistle) silibinin
3 Boswellia (frankincense)
3 Carvacrol
3 Luteolin
3 Lycopene
3 Quercetin
3 Shikonin
3 Thymoquinone
2 Apigenin (mainly Parsley)
2 Berberine
2 Caffeic acid
2 Thymol-Thymus vulgaris
2 Chlorogenic acid
2 EGCG (Epigallocatechin Gallate)
2 Curcumin
2 Honokiol
2 Propolis -bee glue
2 Rosmarinic acid
2 Ursolic acid
1 Silver-NanoParticles
1 Artemisinin
1 Ashwagandha(Withaferin A)
1 Astaxanthin
1 beta-glucans
1 Baicalein
1 Betulinic acid
1 Bromelain
1 Chrysin
1 Ellagic acid
1 Piperine
1 Emodin
1 Gambogic Acid
1 Oleocanthal
1 Phenethyl isothiocyanate
1 Piperlongumine
1 Resveratrol
1 Sulforaphane (mainly Broccoli)
1 Urolithin
1 Vitamin K2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:105  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page